Biogen

Phone: +1 781-464-2000

Web:https://www.biogen.com

Formerly Biogen Idec Inc.
(2003–2015)
Type Public company
Traded as
  • Nasdaq: BIIB
  • NASDAQ-100 component
  • S&P 500 component
Industry Biotechnology
Founded 1978 (1978)
Founders Kenneth Murray
Phillip Allen Sharp
Walter Gilbert
Heinz Schaller
Charles Weissmann
Headquarters Cambridge, Massachusetts, U.S.
Key people Stelios Papadopoulos (Chairman)
Michel Vounatsos (CEO)
Products Avonex, Fampyra, Plegridy, Tecfidera, Tysabri, Spinraza
Revenue Decrease US$10.981 billion (2021)
Operating income Decrease US$2.84 billion (2021)
Net income Decrease US$1.727 billion (2021)
Total assets Decrease US$23.877 billion (2021)
Total equity Increase US$10.96 billion (2021)
Number of employees 9,100 (2020)
Website biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

For detailed contact information visit location pages below.

Biogen's locations around the world

OceaniaExpand

Clinical Trials sponsored by Biogen

3
Abonnieren